Cartesian Therapeutics, Inc.
RNAC
Rankning i aktier
#18138
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Aktiekurs
$6.44
Senast synkroniserad: 2026-10-21
Marknadsvärde
$194.84M
Förändring (1 dag)
0.70%
Förändring (1 år)
865.08%
Land
US
Handel Cartesian Therapeutics, Inc. (RNAC)
Kategori
Healthcare
Aktiekurshistorik för Cartesian Therapeutics, Inc. (RNAC)
Högsta slutkurs: $0.79 den 2023-12-01
Lägsta slutkurs: $14.00 den 2016-06-01
Lägsta slutkurs: $14.00 den 2016-06-01
Aktiekurshistorik för Cartesian Therapeutics, Inc. från 2016 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2023 | -33.64% |
| 2022 | -62.77% |
| 2021 | 0.01% |
| 2020 | 73.71% |
| 2019 | -58.81% |
| 2018 | -55.20% |
| 2017 | -51.08% |
| 2016 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.21 | 7.77% |
CH
|
